Yuanpeng Xia

Yuanpeng Xia


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2021 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
FZFeng Zhang
Feng Zhang
XGXiaoqing Guo
Xiaoqing Guo
YXYuanpeng Xia
Yuanpeng Xia
LMLing Mao
Ling Mao

30 January 2020 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
BLBowei Li
Bowei Li
YXYuanpeng Xia
Yuanpeng Xia
BHBo Hu
Bo Hu
Atherosclerotic vascular disease (ASVD) is a chronic process, with a progressive course over many years, but it can cause acute clinical events, including acute coronary syndromes (ACS), myocardial infarction (MI) and stroke. In addition to a series of typical risk factors for atherosclerosis, like hyperlipidemia, hypertension, smoking and obesity, emerging evidence suggests that atherosclerosis is a chronic inflammatory disease, suggesting that chronic infection plays an important role in the development of atherosclerosis. Toll-like receptors (TLRs) are the most characteristic members of pattern recognition receptors (PRRs), which play an important role in innate immune mechanism. TLRs play different roles in different stages of infection of atherosclerosis-related pathogens such asChlamydia pneumoniae(C. pneumoniae),periodontal pathogens includingPorphyromonas gingivalis(P. gingivalis), Helicobacter pylori(H. pylori) andhuman immunodeficiency virus(HIV). Overall, activation of TLR2 and 4 seems to have a profound impact on infection-related atherosclerosis. This article reviews the role of TLRs in the process of atherosclerosis afterC. pneumoniaeand other infections and the current status of treatment, with a view to providing a new direction and potential therapeutic targets for the study of ASVD.

1 October 2018 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
SYShuai Yang
Shuai Yang
ZYZi-Ming Ye
Zi-Ming Ye
SCShengcai Chen
Shengcai Chen
XLXue-Ying Luo
Xue-Ying Luo
SCShao-Li Chen
Shao-Li Chen
BHBo Hu
Bo Hu

17 March 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YBYing Bi
Ying Bi
JSJing Shen
Jing Shen
SCSheng-Cai Chen
Sheng-Cai Chen
JCjixiang chen
jixiang chen
YXYuanpeng Xia
Yuanpeng Xia
The purpose of this study was to investigate whether baseline neutrophil to lymphocyte ratio (NLR) was an independent predictor for early symptomatic intracranial hemorrhage (sICH), poor functional outcome and mortality at 3 months after reperfusion therapy in acute ischemic stroke (AIS) patients. Using PubMed and EMBASE, we searched for literature published before January 19th, 2019. Two reviewers independently confirmed each study’s eligibility, assessed risk of bias, and extracted data. One reviewer combined studies using random effects meta-analysis. 9 studies with 3651 patients were pooled in the meta-analysis. Overall, baseline NLR levels were greater in patients with poor outcome. The standardized mean difference (SMD) in the NLR levels between patients with poor functional outcome (mRS > 2) and good functional outcome (mRS ≤ 2) was 0.54 units (95% credible interval [CI] [0.38, 0.70]). Heterogeneity test showed that there were significant differences between individual studies (p = 0.02; I2 = 72.8%). The NLR levels were associated with sICH in four included studies (n = 2003, SMD = 0.78, 95% [CI] [0.18, 1.38], I2 = 73.9%). Higher NLR levels were positively correlated with 3-month mortality (n = 1389, ES = 1.71, 95% CI [1.01,2.42], p < 0.01, I2 = 0%) when data were used as categorical variables. Our meta-analysis suggests that increased NLR levels are positively associated with greater risk of sICH, 3-month poor functional outcome and 3-month mortality in AIS patients undergoing reperfusion treatments. Although there are some deficits in this study, it may be feasible to predict the prognosis of reperfusion therapy in AIS patients with NLR levels.

1 October 2021 in Biochemical Pharmacology
Verified
Journal Article
Closed access
XGXiaoqing Guo
Xiaoqing Guo
QLQin Li
Qin Li
SPShulan Pi
Shulan Pi
YXYuanpeng Xia
Yuanpeng Xia
LMLing Mao
Ling Mao

20 October 2021 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
BLBo‐Wei Li
Bo‐Wei Li
YLYu Liu
Yu Liu
LZLei Zhang
Lei Zhang
XGXiao‐Qing Guo
Xiao‐Qing Guo
CWCheng Wen
Cheng Wen
YXYuanpeng Xia
Yuanpeng Xia